European Union
European Commission Approves Kanuma for Lysosomal Acid Lipase Deficiency
The European Commission has approved Kanuma, an innovative enzyme replacement therapy (ERT), for patients of all ages with lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease. This approval marks a significant milestone for patients with LAL-D, who suffer from multi-organ damage and premature death. Kanuma has